collection
Collections Most Read Papers - Cancer Scie...

Most Read Papers - Cancer Science & Oncogenesis

https://read.qxmd.com/read/38320590/update-on-antiphospholipid-syndrome
#1
JOURNAL ARTICLE
Maria G Tektonidou
No abstract text is available yet for this article.
February 6, 2024: Rheumatology
https://read.qxmd.com/read/38493484/management-of-adult-patients-with-cmml-undergoing-allo-hct-recommendations-from-the-ebmt-ph-g-committee
#2
JOURNAL ARTICLE
Francesco Onida, Nico Gagelmann, Yves Chalandon, Guido Kobbe, Marie Robin, Argiris Symeonidis, Theo M de Witte, Raphaël A Itzykson, Madlen Jentzsch, Uwe Platzbecker, Valeria Santini, Guillermo F Sanz, Christoph Scheid, Eric Solary, Peter Valent, Raffaela Greco, Isabel Sánchez-Ortega, Ibrahim Yakoub-Agha, Lisa Pleyer
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly as patients with CMML are mostly older and comorbid. Therefore, the decision between a non-intensive treatment approach and allo-HCT represents a delicate balance, especially since prospective randomized studies are lacking and retrospective data in the literature is conflicting...
March 17, 2024: Blood
https://read.qxmd.com/read/35986748/how-to-improve-intubation-in-the-intensive-care-unit-update-on-knowledge-and-devices
#3
REVIEW
Audrey De Jong, Sheila Nainan Myatra, Oriol Roca, Samir Jaber
Tracheal intubation in the critically ill is associated with serious complications, mainly cardiovascular collapse and severe hypoxemia. In this narrative review, we present an update of interventions aiming to decrease these complications. MACOCHA is a simple score that helps to identify patients at risk of difficult intubation in the intensive care unit (ICU). Preoxygenation combining the use of inspiratory support and positive end-expiratory pressure should remain the standard method for preoxygenation of hypoxemic patients...
October 2022: Intensive Care Medicine
https://read.qxmd.com/read/38192798/pyroptosis-related-signatures-predict-immune-characteristics-and-prognosis-in-ipf
#4
JOURNAL ARTICLE
Yijun He, Tingting Yao, Yan Zhang, Lingzhi Long, Guoliang Jiang, Xiangyu Zhang, Xin Lv, Yuanyuan Han, Xiaoyun Cheng, Mengyu Li, Mao Jiang, Zhangzhe Peng, Lijian Tao, Jie Meng
The purpose of this work was to use integrated bioinformatics analysis to screen for pyroptosis-related genes (PRGs) and possible immunological phenotypes linked to the development and course of IPF. Transcriptome sequencing datasets GSE70866, GSE47460 and GSE150910 were obtained from GEO database. From the GSE70866 database, 34 PRGs with differential expression were found in IPF as compared to healthy controls. In addition, a diagnostic model containing 4 genes PRGs (CAMP, MKI67, TCEA3 and USP24) was constructed based on LASSO logistic regression...
January 15, 2024: Heliyon
https://read.qxmd.com/read/38426268/acute-and-non-acute-decompensation-of-liver-cirrhosis-47-130
#5
REVIEW
Martin S Schulz, Paolo Angeli, Jonel Trebicka
In the traditional view, the occurrence of cirrhosis-related complications, such as hepatic encephalopathy, formation of ascites or variceal haemorrhage, marks the transition to the decompensated stage of cirrhosis. Although the dichotomous stratification into a compensated and decompensated state reflects a prognostic water-shed moment and remains to hold its prognostic validity, it represents an oversimplification of clinical realities. A broadening understanding of pathophysiological mechanisms underpinning decompensation have led to the identification of distinct prognostic subgroups, associated with different clinical courses following decompensation...
March 1, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
https://read.qxmd.com/read/38450850/chronic-myelomonocytic-leukemia-2024-update-on-diagnosis-risk-stratification-and-management
#6
JOURNAL ARTICLE
Mrinal M Patnaik, Ayalew Tefferi
DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, characterized by prominent monocytosis and an inherent risk for leukemic transformation (~15%-20% over 3-5 years). DIAGNOSIS: Newly revised diagnostic criteria include sustained (>3 months) peripheral blood (PB) monocytosis (≥0.5 × 109 /L; monocytes ≥10% of leukocyte count), consistent bone marrow (BM) morphology, <20% BM or PB blasts (including promonocytes), and cytogenetic or molecular evidence of clonality...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/38348231/treatment-and-management-of-acinetobacter-pneumonia-lessons-learned-from-recent-world-event
#7
REVIEW
Karyne Rangel, Salvatore Giovanni De-Simone
Acinetobacter pneumonia is a significant healthcare-associated infection that poses a considerable challenge to clinicians due to its multidrug-resistant nature. Recent world events, such as the COVID-19 pandemic, have highlighted the need for effective treatment and management strategies for Acinetobacter pneumonia. In this review, we discuss lessons learned from recent world events, particularly the COVID-19 pandemic, in the context of the treatment and management of Acinetobacter pneumonia. We performed an extensive literature review to uncover studies and information pertinent to the topic...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38450790/2024-update-on-allogeneic-hematopoietic-stem-cell-transplant-for-myelofibrosis-a-review-of-current-data-and-applications-on-risk-stratification-and-management
#8
JOURNAL ARTICLE
Haris Ali, Andrea Bacigalupo
BACKGROUND: Allogeneic hemopoietic stem cell transplantation (HSCT) currently remains the only curative treatment for patients with myelofibrosis (MF). Transplant related mortality (TRM) and relapse, remain two significant complications which need to be addressed. AIMS: The aim of this manuscript is to review current available reports on changes which have recently occurred, to improve the outcome of MF patients undergoing an allogeneic HSCT. METHODS: Published papers were used to analyze different aspects of allogeneic HSCT...
March 7, 2024: American Journal of Hematology
https://read.qxmd.com/read/38375783/the-mozart-effect-in-chronic-myeloid-leukaemia
#9
JOURNAL ARTICLE
Jesper Stentoft
Clinical research has not been able to establish whether the differences between first- and second-generation BCR-ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge-paradoxically in the absence of the drugs-as demonstrated by differences in the relapse kinetics after cessation of therapy. Commentary on: Alcazer et al. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients...
February 20, 2024: British Journal of Haematology
https://read.qxmd.com/read/38485723/ptcy-versus-atg-as-graft-versus-host-disease-prophylaxis-in-mismatched-unrelated-stem-cell-transplantation
#10
JOURNAL ARTICLE
Olaf Penack, Mouad Abouqateb, Christophe Peczynski, William Boreland, Zafer Gülbas, Tobias Gedde-Dahl, Cristina Castilla-Llorente, Nicolaus Kröger, Mathias Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Peric
There is an increased risk of GVHD and of non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) when mismatched unrelated donors (MMUD) are used. In Europe, it is standard practice to use rabbit anti-thymocyte globulin (rATG) to reduce the high NRM and GVHD risks after MMUD alloSCT. As an alternative to rATG, post-transplantation Cyclophosphamide (PTCy) is in increasing clinical use. It is currently impossible to give general recommendations regarding preference for one method over another since comparative evidence from larger data sets is lacking...
March 15, 2024: Blood Cancer Journal
https://read.qxmd.com/read/38396839/current-understanding-of-immune-thrombocytopenia-a-review-of-pathogenesis-and-treatment-options
#11
REVIEW
Alina Mititelu, Minodora-Cezarina Onisâi, Adrian Roșca, Ana Maria Vlădăreanu
The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients' quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking...
February 10, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38339417/management-of-hepatocellular-carcinoma-in-2024-the-multidisciplinary-paradigm-in-an-evolving-treatment-landscape
#12
REVIEW
Emily Kinsey, Hannah M Lee
Liver cancer is the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) makes up the majority of liver cancer cases. Despite the stabilization of incidence rates in recent years due to effective viral hepatitis treatments, as well as improved outcomes from early detection and treatment advances, the burden of HCC is anticipated to rise again due to increasing rates of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease. The treatment landscape is evolving and requires a multidisciplinary approach, often involving multi-modal treatments that include surgical resection, transplantation, local regional therapies, and systemic treatments...
February 4, 2024: Cancers
https://read.qxmd.com/read/38350768/covid-19-vaccines-and-adverse-events-of-special-interest-a-multinational-global-vaccine-data-network-gvdn-cohort-study-of-99-million-vaccinated-individuals
#13
JOURNAL ARTICLE
K Faksova, D Walsh, Y Jiang, J Griffin, A Phillips, A Gentile, J C Kwong, K Macartney, M Naus, Z Grange, S Escolano, G Sepulveda, A Shetty, A Pillsbury, C Sullivan, Z Naveed, N Z Janjua, N Giglio, J Perälä, S Nasreen, H Gidding, P Hovi, T Vo, F Cui, L Deng, L Cullen, M Artama, E Weintraub, H Lu, H J Clothier, K Batty, J Paynter, H Petousis-Harris, J Buttery, S Black, A Hviid
BACKGROUND: The Global COVID Vaccine Safety (GCoVS) Project, established in 2021 under the multinational Global Vaccine Data Network™ (GVDN®), facilitates comprehensive assessment of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from 10 sites across eight countries. METHODS: Using a common protocol, this observational cohort study compared observed with expected rates of 13 selected AESI across neurological, haematological, and cardiac outcomes...
February 12, 2024: Vaccine
https://read.qxmd.com/read/37195076/american-society-of-hematology-2023-guidelines-for-management-of-venous-thromboembolism-thrombophilia-testing
#14
JOURNAL ARTICLE
Saskia Middeldorp, Robby Nieuwlaat, Lisa Baumann Kreuziger, Michiel Coppens, Damon Houghton, Andra H James, Eddy Lang, Stephan Moll, Tarra Myers, Meha Bhatt, Chatree Chai-Adisaksopha, Luis E Colunga-Lozano, Samer G Karam, Yuan Zhang, Wojtek Wiercioch, Holger J Schünemann, Alfonso Iorio
Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables...
November 28, 2023: Blood Advances
https://read.qxmd.com/read/38440808/hairy-cell-leukemia-2024-update-on-diagnosis-risk-stratification-and-treatment-annual-updates-in-hematological-malignancies
#15
JOURNAL ARTICLE
Xavier Troussard, Elsa Maître, Jérôme Paillassa
DISEASE OVERVIEW: Hairy cell leukemia (HCL) and HCL-like disorders, including HCL variant (HCL-V) and splenic diffuse red pulp lymphoma (SDRPL), are a very heterogenous group of mature lymphoid B-cell disorders characterized by the identification of hairy cells, a specific genetic profile, a different clinical course and the need for appropriate treatment. DIAGNOSIS: Diagnosis of HCL is based on morphological evidence of hairy cells, an HCL immunologic score of 3 or 4 based on the CD11c, CD103, CD123, and CD25 expression, the trephine biopsy which makes it possible to specify the degree of tumoral bone marrow infiltration and the presence of BRAFV600E somatic mutation...
March 5, 2024: American Journal of Hematology
https://read.qxmd.com/read/38407943/targeting-autophagy-overcomes-cancer-intrinsic-resistance-to-car-t-immunotherapy-in-b-cell-malignancies
#16
JOURNAL ARTICLE
Lu Tang, Huan Zhang, Fen Zhou, Qiuzhe Wei, Mengyi Du, Jianghua Wu, Chenggong Li, Wenjing Luo, Jie Zhou, Xindi Wang, Zhaozhao Chen, Yinqiang Zhang, Zhongpei Huang, Zhuolin Wu, Yuxi Wen, Huiwen Jiang, Danying Liao, Haiming Kou, Wei Xiong, Heng Mei, Yu Hu
BACKGROUND: Chimeric antigen receptor T (CAR-T) therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignancies, but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood. This study aims to explore the molecular determinants of cancer cell sensitivity to CAR-T cell-mediated killing and to provide a better understanding of the underlying mechanisms and potential modulation to improve clinical efficacy...
February 26, 2024: Cancer Communications
https://read.qxmd.com/read/38401418/sting-signalling-compensates-for-low-tumour-mutation-burden-to-drive-anti-tumour-immunity
#17
JOURNAL ARTICLE
Jiayi Tan, Colt A Egelston, Weihua Guo, Jeremy M Stark, Peter P Lee
BACKGROUND: While mutation-derived neoantigens are well recognized in generating anti-tumour T cell response, increasing evidences highlight the complex association between tumour mutation burden (TMB) and tumour infiltrating lymphocytes (TILs). The exploration of non-TMB determinants of active immune response could improve the prognosis prediction and provide guidance for current immunotherapy. METHODS: The transcriptomic and whole exome sequence data in The Cancer Genome Atlas were used to examine the relationship between TMB and exhausted CD8+ T cells (Tex), as an indicator of tumour antigen-specific T cells across nine major cancer types...
March 2024: EBioMedicine
https://read.qxmd.com/read/38249542/update-on-therapeutic-approaches-for-invasive-fungal-infections-in-adults
#18
REVIEW
Catherine-Audrey Boutin, Me-Linh Luong
Invasive fungal infections are increasingly encountered with the expansion of iatrogenic immunosuppression, including not only solid organ and hematopoietic stem cell transplant recipients but also patients with malignancies or autoimmune diseases receiving immunomodulatory therapies, such as Bruton Tyrosine Kinase (BTK) inhibitor. Their attributable mortality remains elevated, part of which is a contribution from globally emerging resistance in both molds and yeasts. Because antifungal susceptibility test results are often unavailable or delayed, empiric and tailored antifungal approaches including choice of agent(s) and use of combination therapy are heterogeneous and often based on clinician experience with knowledge of host's net state of immunosuppression, prior antifungal exposure, antifungal side effects and interaction profile, clinical severity of disease including site(s) of infection and local resistance data...
2024: Therapeutic Advances in Infectious Disease
https://read.qxmd.com/read/38291716/clinical-practice-guideline-inconsistent-management-of-fever-and-neutropenia-in-pediatric-oncology-a-children-s-oncology-group-study
#19
JOURNAL ARTICLE
L Lee Dupuis, Brian T Fisher, A J Sugalski, Allison Caren Grimes, Michelle Nuño, S Ramakrishnan, M P Beauchemin, Paula D Robinson, Nancy Santesso, Alexandra Walsh, A R Wrightson, Lolie Yu, Susan K Parsons, Lillian Sung
BACKGROUND: The primary objective was to measure the proportion of episodes where care delivery was inconsistent with selected recommendations of a clinical practice guideline (CPG) on fever and neutropenia (FN) management. The influence of site size on CPG-inconsistent care delivery, and association between patient outcomes and CPG-inconsistent care were described. METHODS: This retrospective, multicenter study included patients less than 21 years old with cancer who were at high risk of poor FN outcomes and were previously enrolled to a Children's Oncology Group (COG) study at participating National Cancer Institute Community Oncology Research Program (NCORP) institutions from January 2014 through December 2015...
January 30, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38413247/international-recommendations-for-screening-and-preventative-practices-for-long-term-survivors-of-transplantation-and-cellular-therapy-a-2023-update
#20
Seth J Rotz, Neel S Bhatt, Betty K Hamilton, Christine Duncan, Mahmoud Aljurf, Yoshiko Atsuta, Kristen Beebe, David Buchbinder, Peggy Burkhard, Paul A Carpenter, Naeem Chaudhri, Mohamed Elemuary, Mahmoud Elsawy, Gregory Mt Guilcher, Nada Hamad, Amado Karduss, Zinaida Peric, Duncan Purtill, Douglas Rizzo, Morgani Rodrigues, Maria Belén Rosales Ostriz, Nina Salooja, Helene Schoemans, Adriana Seber, Akshay Sharma, Alok Srivastava, Susan K Stewart, K Scott Baker, Navneet S Majhail, Rachel Phelan
As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications and international access improves, the number of HCTs performed annually continues to rise. Parallel improvements in HCT techniques and supportive care entails more patients surviving long term, creating further emphasis on survivorship needs. Survivors are at risk for developing late complications secondary to pretransplantation, peritransplantation, and post-transplantation exposures and other underlying risk factors...
February 26, 2024: Transplantation and cellular therapy
label_collection
label_collection
1133
1
2
2024-03-05 00:25:32
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.